Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia

AIDS

Volumn 26, Issue 6, 2012, Pages 776-778

  Aouri, Manel ^a   Decosterd, Laurent A ^a   Buclin, Thierry ^a   Hirschel, Bernard ^b   Calmy, Alexandra ^b   Livio, Françoise ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; DRUG METABOLITE; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSCARNET; TENOFOVIR; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; EVENING DOSAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ASPERGILLOSIS; MORNING DOSAGE; MULTIDRUG RESISTANCE; NOTE; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ASPERGILLOSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PNEUMONIA, ASPIRATION; PYRIDAZINES; PYRIMIDINES; RITONAVIR; TRIAZOLES;

EID: 84859085055     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328351f662     Document Type: Note

References (9)

1. Toy J, Giguère P, Kravcik S, la Porte CJL. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. AIDS 2011; 25:541-542.
2. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, et al. Multiplex ultra-performance liquid chromatographytandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole N-oxide, anidulafungin and caspofungin. Antimicrob Agents Chemother 2010; 54:5303-5315.
3. Fayet A, Beguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, et al. A LC-tandem MSassay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir and etravirine. J Chromatograph B Analyt Technol Biomed Life Sci 2009; 877:1057-1069.
4. Mathias AA, West S, Hui J, Kearney BP. Dose-response ofritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85:64-70.
5. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetics and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011; 50:229-244.
6. Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007; 51:3617-3626. (Pubitemid 47519352)
7. Yakiwchuk EM, Foisy MM, Hughes CA. Complexity ofinteractions between voriconazole and antiretroviral agents. Ann Pharmacother 2008; 42:698-703. (Pubitemid 351619942)
8. FDA Monography Etravirine (Intelence). http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/022187s008lbl.pdf [Last Accessed 7 February 2012]
9. Sekar VJ, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans RM. Pharmacokinetics ofdarunavir/ritonavir and ketoconazole following co-administration in HIV- healthy volunteers. Br J Clin Pharmacol 2008; 66:215-221.